Kiniksa Pharmaceuticals International, plc cash flow to debt ratio of 270.50% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.

Kiniksa Pharmaceuticals International, plc's free cash flow has increased 0.00% from $25.41M last year to $25.41M, signaling increasing performance

Kiniksa Pharmaceuticals International, plc's debt to equity ratio is 0.01, which means that the company's assets are healthy financed, signaling financial stability.

Kiniksa Pharmaceuticals International, plc's debt has decreased relative to shareholder equity from 0.02 last year to 0.01 today, signaling strengthened financials

Kiniksa Pharmaceuticals International, plc has a net cash position, so leverage is healthy.

Kiniksa Pharmaceuticals International, plc earns at least as much interest as it pays. Interest obligations are fully covered.

Kiniksa Pharmaceuticals International, plc's profit margin was -10.21% last year and is 11.58% this year, signaling increasing performance

Kiniksa Pharmaceuticals International, plc's short-term assets of $527.18M exceed its short-term liabilities of $139.18M

Kiniksa Pharmaceuticals International, plc's return on assets of 11.14% is higher than the 5.00% threshold, indicating efficient asset utilization

Kiniksa Pharmaceuticals International, plc's return on equity of 17.27%, is higher than 15.00%, indicating good performance

Kiniksa Pharmaceuticals International, plc's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Kiniksa Pharmaceuticals International, plc had positive net income in 3 out of 5 years, indicating stable and consistent earnings

Kiniksa Pharmaceuticals International, plc has positive free cash flow, indicating the company generates cash after capital expenditures

Kiniksa Pharmaceuticals International, plc has a free cash flow yield of 0.34%, which is below the 2.00% threshold, indicating limited cash return relative to market value

Kiniksa Pharmaceuticals International, plc's yearly earnings has increased 236.61% since last year from $-43.19M to $59.01M, signaling increasing performance

Kiniksa Pharmaceuticals International, plc's yearly revenue has increased 60.09% since last year from $423.24M to $677.56M, signaling increasing performance

ROIC 12.30% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

Kiniksa Pharmaceuticals International, plc's 3-year revenue CAGR of 45.45% is positive, indicating growing revenue over the past 3 years

Kiniksa Pharmaceuticals International, plc had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Kiniksa Pharmaceuticals International, plc had positive ROE in 3 out of 5 years, indicating consistent and reliable returns on equity

Kiniksa Pharmaceuticals International, plc has insufficient data to evaluate this check.

Kiniksa Pharmaceuticals International, plc has an earnings yield of 1.49%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings

Kiniksa Pharmaceuticals International, plc is overvalued relative to its fair value price of 0.00 based on Base EBITDA Valuation model

Kiniksa Pharmaceuticals International, plc has an EV/EBITDA ratio of 77.08x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings

Kiniksa Pharmaceuticals International, plc has insufficient data to evaluate this check.

Kiniksa Pharmaceuticals International, plc had non-positive diluted EPS five years ago; the PEG ratio is not meaningful and the check fails.

Kiniksa Pharmaceuticals International, plc has a price-to-book ratio of 10.33x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Kiniksa Pharmaceuticals International, plc has a price-to-sales ratio of 7.76x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue